Rigel Pharmaceuticals Q3 net income drops 53% to $13.19 million

PUBT · 2d ago
Rigel Pharmaceuticals Q3 net income drops 53% to $13.19 million
  • Rigel Pharmaceuticals’ third-quarter 2026 net income fell 53% year over year to $13.19 million.
  • Total revenues rose 16% year over year to $80.89 million.
  • Total costs and expenses climbed 55% year over year to $63.79 million, partly due to higher research and development costs.
  • VEPPANU became commercially available August 13, with shipments to more than 100 patients and clinics in its first six weeks.
  • The updated 2026 outlook projects total revenues of approximately $290 million to $295 million, excluding VEPPANU, with positive full-year net income.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051601PR_NEWS_USPR_____SF89772) on November 05, 2026, and is solely responsible for the information contained therein.